Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Average Rating of “Hold” by Analysts

Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) have been assigned a consensus recommendation of “Hold” from the six research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $17.50.

Several analysts recently weighed in on the company. HC Wainwright downgraded Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. Weiss Ratings cut Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, June 11th. Oppenheimer upped their price target on shares of Entrada Therapeutics from $21.00 to $23.00 and gave the stock an “outperform” rating in a research note on Monday, April 6th. Wall Street Zen downgraded Entrada Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Finally, Cantor Fitzgerald initiated coverage on shares of Entrada Therapeutics in a research note on Wednesday, April 1st. They issued an “overweight” rating for the company.

Entrada Therapeutics Price Performance

Shares of NASDAQ TRDA opened at $7.40 on Friday. Entrada Therapeutics has a 1 year low of $4.93 and a 1 year high of $16.45. The stock has a market cap of $287.28 million, a P/E ratio of -1.85 and a beta of -0.26. The firm has a 50-day moving average of $7.48 and a 200 day moving average of $10.27.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.95) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.11. Entrada Therapeutics had a negative net margin of 2,895.05% and a negative return on equity of 51.22%. The business had revenue of $0.88 million for the quarter, compared to analysts’ expectations of $2.92 million. Research analysts expect that Entrada Therapeutics will post -4.12 earnings per share for the current fiscal year.

Insider Transactions at Entrada Therapeutics

In related news, Director Bernhardt G. Zeiher purchased 5,000 shares of Entrada Therapeutics stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $5.86 per share, with a total value of $29,300.00. Following the purchase, the director directly owned 5,000 shares of the company’s stock, valued at approximately $29,300. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Nathan J. Dowden sold 15,000 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $15.33, for a total value of $229,950.00. Following the transaction, the chief operating officer owned 198,588 shares in the company, valued at $3,044,354.04. The trade was a 7.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 9.49% of the company’s stock.

Institutional Trading of Entrada Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC raised its stake in Entrada Therapeutics by 9.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock valued at $176,000 after buying an additional 1,560 shares during the last quarter. Alliancebernstein L.P. grew its stake in shares of Entrada Therapeutics by 7.1% during the third quarter. Alliancebernstein L.P. now owns 24,320 shares of the company’s stock worth $141,000 after acquiring an additional 1,620 shares during the last quarter. Great Lakes Advisors LLC increased its holdings in shares of Entrada Therapeutics by 5.5% during the fourth quarter. Great Lakes Advisors LLC now owns 43,268 shares of the company’s stock valued at $445,000 after acquiring an additional 2,239 shares in the last quarter. Quadrature Capital Ltd increased its holdings in shares of Entrada Therapeutics by 13.5% during the fourth quarter. Quadrature Capital Ltd now owns 20,318 shares of the company’s stock valued at $209,000 after acquiring an additional 2,424 shares in the last quarter. Finally, First Trust Advisors LP raised its position in shares of Entrada Therapeutics by 3.6% in the 2nd quarter. First Trust Advisors LP now owns 75,120 shares of the company’s stock valued at $505,000 after purchasing an additional 2,631 shares during the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.